The proportion of poorly soluble drug compounds in the development pipeline is on the rise, with 70% to 90% of current pipeline drugs falling in the two low-solubility classes of the biopharmaceutical classification system.
With the emergence of new techniques to improve solubility, low solubility compounds are more likely to advance to the clinic.
However, the large spectrum of available technologies can make it challenging for the formulation scientist to proceed in an informed and rational manner.
Download to find out more.
Thank you.Please check your email to download the white paper.